Pharma Business Updates
Eli Lilly to buy Scorpion Therapeutics' cancer therapy for up to $2.5 billion
January 13, 2025 at 14:17
Jan 13 (Reuters) - Eli Lilly (LLY.N, opens new tab said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments.
The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors.
The therapy is a PI3K inhibitor, which selectively targets a type of protein called PI3K.
"We look forward to leveraging the great work of the Scorpion team to date, along with Lilly's deep expertise in breast cancer, to further advance STX-478 with speed and focus," said Jacob Van Naarden, president of Lilly Oncology.
The agreement includes an upfront payment and subsequent payments upon achieving certain regulatory and sales milestones.
As part of the deal, Scorpion will spin out a new entity to house its non-PI3K pipeline assets and employees. The new, independent company will be owned by Scorpion's current shareholders, with Lilly holding a minority equity interest.
Reporting by Sneha S K; Editing by Shilpi Majumdar and Shounak Dasgupt
Keywords
Newer articles
In case you missed it
<p> Artistic director collects award at Paris fashion week while rumour mill suggests Gucci, Burberry or Margiela move</p>
Eric Adams’s Totally Predictable MAGA Turn
US suspends aid to Ukraine – Politico
The Unchecked Authority of Trump’s Immigration Orders
Israeli hostages freed by Hamas
Donald Trump fires at least 17 independent federal inspectors
It’s the 80th anniversary of the liberation of Auschwitz. Photos from that day
Trump drops announcement on TikTok’s fate and America’s digital future
DeepSeek AI chatbot bursts onto the scene—is the US losing its tech edge to China?
Hezbollah is not defeated and is re-emerging in Lebanon - analysis